T1	p 262 297	individuals > or =60 years of age .
T2	p 413 414	)
T3	p 464 533	frozen ) in subjects > or =50 years of age . Subjects with a negative
T4	p 565 568	1:1
T5	p 639 687	1:2 by age ( 50 to 59 years and > or =60 years )
T6	p 1124 1127	n =
T7	p 1138 1150	frozen ( n =
T8	i 98 129	refrigerator-stable formulation
T9	i 133 143	Zostavax .
T10	i 148 164	vaccine Zostavax
T11	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T12	i 441 472	formulation ( Zostavax frozen )
T13	i 739 765	. Varicella-zoster virus (
T14	i 810 856	glycoprotein enzyme-linked immunosorbent assay
T15	i 859 866	gpELISA
T16	i 998 999	;
T17	i 1109 1121	refrigerated
T18	i 1138 1144	frozen
T19	i 1284 1314	formulation/frozen formulation
T20	i 1905 1913	Zostavax
T21	o 72 86	immunogenicity
T22	o 210 211	)
T23	o 322 328	safety
T24	o 337 351	immunogenicity
T25	o 690 696	Safety
T26	o 723 763	postvaccination . Varicella-zoster virus
T27	o 766 790	VZV ) antibody responses
T28	o 810 850	glycoprotein enzyme-linked immunosorbent
T29	o 902 943	VZV antibody geometric mean titer ( GMT ;
T30	o 959 997	VZV antibody geometric mean rise ( GMR
T31	o 1025 1089	incidence of vaccine-related serious adverse experiences ( AEs )
T32	o 1178 1198	similar GMTs ( 727.4
T33	o 1249 1270	estimated GMT ratio (
T34	o 1424 1451	vaccine-related serious AEs
T35	o 1492 1498	safety
T36	o 1572 1590	injection-site AEs
T37	o 1747 1759	systemic AEs
T38	o 1806 1825	vaccine-related AEs
T39	o 1932 1938	safety
T40	o 1957 1968	immunogenic